KLOW for Women: Skin, Hair, Inflammation and What the Research Covers

This is the research women most often have in mind when they ask about KLOW, and it is worth reading precisely. Cosmetic-science studies in human volunteers have evaluated GHK-Cu creams, mostly in women with photoaged facial skin, over 8 to 12 weeks, and reported changes in skin density, thickness, firmness, fine lines and clarity measured by instruments and by dermatologists. Most of that work appeared in conference proceedings and industry-funded reports rather than peer-reviewed journals; a 2015 review in BioMed Research International summarises it.

What it shows. That copper peptide creams changed measured skin properties in small groups of mostly female volunteers.

What it does not show. Anything about injected GHK-Cu, or about GHK-Cu combined with three other peptides. The studies were small, short and mostly not independently published. Whether an injection under the skin of the abdomen does for facial skin what a cream applied to the face was reported to do has not been tested. GHK-Cu topical vs injection sets out that gap.

The dermatology literature describes a marked drop in dermal collagen in the years after the final period, and collagen loss accelerating in the years around menopause is the reason GHK-Cu comes up for women in their forties and fifties. The live guidance places GHK-Cu alongside retinoids and sun protection, not in place of them. No study has tested GHK-Cu, by any route, specifically in perimenopausal or postmenopausal skin. The wider picture is in peptides for skin and peptides for menopause.

The hair research for KLOW's components is copper-peptide follicle work in mice and rats (1991 and 1993), a 2007 dish study of human follicles using a related copper tripeptide, and a 2004 FASEB Journal paper reporting that thymosin beta-4, the protein TB-500 is a fragment of, increased hair growth in rats and mice by acting on follicle stem cells. BPC-157 and KPV have no hair research. No trial has tested KLOW or any of its components in women with hair loss.

KPV is what separates KLOW from the three-peptide GLOW. Cell and animal studies describe it interfering with NF-kB signalling and reducing pro-inflammatory cytokines such as TNF-alpha and IL-6, and a 2008 paper in Gastroenterology reported reduced inflammation in mouse colitis models, with KPV taken up into gut cells by the PepT1 transporter; much of that work gave KPV in drinking water rather than by injection. There is no human trial of KPV for any indication.

The injury case rests on BPC-157 and, by extension from the full-length protein, on TB-500. A 2003 paper in the Journal of Orthopaedic Research reported faster reattachment after Achilles tendon transection in rats, and a 2011 paper in the Journal of Applied Physiology reported greater tendon outgrowth in rat explants. There are no randomized trials of BPC-157 or TB-500 in humans for tendon or soft-tissue injury, and none reports results for women.

Hair shedding is one of the commonest reasons women ask about copper peptides, and in this decade it is at least as often thyroid disease, iron deficiency or female-pattern hair loss as anything a peptide addresses. Iron deficiency is far more common in women because of menstrual blood loss, and ferritin can be low while a full blood count reads normal. Autoimmune thyroid disease is heavily skewed toward women. Postpartum shedding is a synchronised shift of follicles into a resting phase and usually resolves untreated, and a peptide is not appropriate while breastfeeding regardless. KLOW is not a treatment for female-pattern hair loss and not a substitute for established hair-loss treatment. More in peptides for hair growth.

Because KPV comes from alpha-MSH, the hormone best known for pigmentation, women sometimes ask whether KLOW darkens skin or worsens uneven pigment. It is not expected to. KPV is the fragment that keeps alpha-MSH's anti-inflammatory signalling and drops the pigmentation effect. Any darkening of skin or moles is a reason to stop and report it. The product that does drive pigmentation, Melanotan II, is not in KLOW.

KLOW is not used in pregnancy or while breastfeeding. The repair peptides, BPC-157, TB-500, GHK-Cu and KPV, have largely preclinical evidence overall and no pregnancy data at all. Absence of data is not evidence of safety. If you become pregnant on treatment, stop and contact your physician the same day. Can you take peptides while pregnant covers why.

None of the four components has human fertility data. Nothing in their research describes an effect on the reproductive hormone axis, on ovulation or on early pregnancy, because nothing in it looked. If conception is a goal in any timeframe you can name, raise it with your physician before starting. See do peptides affect fertility.

None of the four is a hormone or acts on the reproductive axis, and none is described as affecting hormonal contraception. No study has looked at that directly, so any change in your cycle on treatment is worth reporting, even if another cause is likelier. This is a real difference from the GLP-1 medications, which carry their own contraception conversation; see peptides for women.

GHK-Cu delivers copper, which matters for anyone with Wilson's disease or another copper-metabolism disorder, where KLOW is ruled out, and for anyone taking high-dose zinc, which competes with copper. Every GHK-Cu blend carries a full 50 mg, so two GHK-Cu products at once doubles the copper. If you already use GHK-Cu, GLOW or RADIANCE, say so on your intake.

The components are described as supporting new blood-vessel growth, which is why a personal history of cancer is on the caution list. A history of breast, ovarian or endometrial cancer goes on the intake in full.

The 2026 World Anti-Doping Code Prohibited List names BPC-157 in S0 and lists thymosin beta-4 and its derivatives, TB-500 included, under S2.3, both prohibited at all times. A blend is prohibited by virtue of its components, so KLOW is not an option for any woman in a testing pool, and a prescription does not create an exemption. See is TB-500 banned in sports and peptides for athletes.